Phreesia, Inc. (NYSE:PHR) CFO Sells $85,018.95 in Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 3,195 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $26.61, for a total value of $85,018.95. Following the transaction, the chief financial officer now owns 148,509 shares in the company, valued at approximately $3,951,824.49. This represents a 2.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Balaji Gandhi also recently made the following trade(s):

• On Tuesday, October 15th, Balaji Gandhi sold 864 shares of Phreesia stock. The shares were sold at an average price of $21.03, for a total transaction of $18,169.92.

Phreesia Stock Performance

NYSE:PHR traded up $1.44 during midday trading on Wednesday, hitting $28.42. The company’s stock had a trading volume of 668,317 shares, compared to its average volume of 410,783. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.77. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $29.16. The firm’s 50 day moving average is $22.30 and its 200-day moving average is $22.49. The firm has a market cap of $1.65 billion, a P/E ratio of -19.33 and a beta of 0.94.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.04. The company had revenue of $106.80 million for the quarter, compared to the consensus estimate of $106.33 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The firm’s revenue for the quarter was up 16.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.58) EPS. Equities analysts anticipate that Phreesia, Inc. will post -1.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Phreesia

Several institutional investors have recently made changes to their positions in PHR. International Assets Investment Management LLC boosted its position in Phreesia by 2,179.7% during the third quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock worth $33,000 after purchasing an additional 1,395 shares in the last quarter. Lombard Odier Asset Management USA Corp acquired a new stake in shares of Phreesia in the second quarter valued at about $202,000. Point72 DIFC Ltd acquired a new position in shares of Phreesia during the 2nd quarter worth about $209,000. XTX Topco Ltd purchased a new position in shares of Phreesia in the third quarter valued at approximately $247,000. Finally, Hsbc Holdings PLC purchased a new position in Phreesia in the 2nd quarter valued at $301,000. 92.10% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on PHR shares. JMP Securities reissued a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a report on Tuesday, December 10th. Needham & Company LLC restated a “buy” rating and set a $29.00 price objective on shares of Phreesia in a research note on Tuesday, December 10th. Royal Bank of Canada upgraded Phreesia from a “sector perform” rating to an “outperform” rating and lifted their target price for the company from $24.00 to $32.00 in a research note on Wednesday. KeyCorp increased their price target on shares of Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Truist Financial boosted their price objective on shares of Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Eleven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Phreesia has a consensus rating of “Buy” and an average target price of $30.64.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.